SCOPE International AG is an independent Full-Service Contract Research Organization (CRO) headquartered in Germany. With a network of 14 local offices and business entities throughout Europe, SCOPE offers clinical development and consulting services to the pharmaceutical, biotechnology, and medical device industries. Their focus on cost-effective services and industry-leading benchmarks in timelines, costs, and quality has made them a trusted partner in managing major indications in clinical phases I – IV.
Established in 2000, SCOPE has conducted over 260 studies with 70,000 patients across 30 countries worldwide. Their extensive experience and expertise position them as a reliable partner for tailored solutions and seamless guidance through all phases of development. Emphasizing a people-centric approach, SCOPE's slogan, "Your Full-Service CRO – We work with people for people," underlines their commitment to collaborative and personalized support for their clients.
SCOPE International AG holds promise for potential venture capitalist interest, especially for investors seeking opportunities in the pharmaceutical and biotechnology sectors. The company's impressive track record, strong network, and dedication to excellence in clinical research and development make it a compelling candidate for investment consideration. With their solid foundation and comprehensive service offerings, SCOPE presents an exciting prospect for investors looking to support impactful innovations in the healthcare industry.
There is no investment information
No recent news or press coverage available for SCOPE International AG.